EUVIMEDObjevte EUVIMED
Crossref

Preliminary Insights Into the Combined Antitumor Efficacy of Onco‐VV‐TT and Natural Killer Cells in Glioblastoma

Seyedeh Nasim Mirbahari iD, Davood Sanooghi iD, Marzieh Ebrahimi iD, Hamid Mahdizadeh iD, Ali Davari iD, Amir-Abbas Hedayati Asl iD, Sahel Ahmadpour Torkamani iD, Mahdi Hesaraki iD, Mehdi Totonchi iD

Cell Biology International · 2026-06 · 50 (6)

DOI: 10.1002/cbin.70176 ↗

At a glance

Journal article in Cell Biology International, published online on 2026-06-12. Written by Seyedeh Nasim Mirbahari and 8 co-authors. Institution: Department of Developmental Biology, School of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran. Major MEDLINE topics: Killer Cells, Natural, Glioblastoma, Vaccinia virus, Oncolytic Virotherapy. 35 references. Funded by: Royan Lotus Charity Foundation, Royan Institute, Royan TuCAGene Ltd.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

This study investigates the therapeutic efficacy and safety of Onco‐VV‐TT, a genetically engineered oncolytic vaccinia virus, in the treatment of glioblastoma (GBM), with and without the combination of natural killer (NK) cell immunotherapy. A comprehensive set of in vitro and in vivo experiments was conducted to assess viral cytotoxicity, replication, tumor penetration, and immunomodulatory effects. Onco‐VV‐TT selectively reduced the viability of GBM cell lines (U251, U87, and C6) in a time‐ and dose‐dependent manner while sparing normal fibroblasts. The virus significantly impaired clonogenicity, migration, and stemness‐related gene expression in U251 cells. Confocal imaging confirmed viral replication and deep penetration into 3D spheroids. NK cells demonstrated strong cytotoxicity against U251 cells in both 2D and 3D models. In a xenograft mouse model, intratumoral administration of Onco‐VV‐TT suppressed tumor growth and significantly prolonged survival; NK cell monotherapy showed limited efficacy, while the addition of NK cells further enhanced therapeutic outcomes. Immunological analyses revealed that combination therapy elevated pro‐inflammatory cytokines (TNF‐α, IFN‐γ, and IL‐6) and increased WBC count, reflecting an expected transient systemic inflammatory response to vaccinia virus exposure rather than a direct enhancement of antitumor immunity. Histopathological and immunohistochemical analysis showed reduced mitosis, increased apoptosis, decreased cancer stem cell marker CD133, and lower VEGF expression in tumors treated with Onco‐VV‐TT and NK cells. Safety evaluations in immunocompetent mice demonstrated no significant systemic toxicity or organ damage following intravenous injection of Onco‐VV‐TT. Transient inflammatory marker elevation resolved by day 21, and all hematological and biochemical parameters remained within normal range. These findings suggest that Onco‐VV‐TT, particularly in combination with NK cell therapy, is a promising and well‐tolerated approach for GBM treatment, meriting further preclinical and clinical development.

Subjects

MeSH terms (MEDLINE)

Killer Cells, NaturalGlioblastomaVaccinia virusOncolytic VirotherapyBrain NeoplasmsAnimalsHumansCell Line, TumorMiceXenograft Model Antitumor AssaysCombined Modality TherapyOncolytic VirusesImmunotherapyMice, Nude

Author keywords

glioblastomaimmunovirotherapynatural killer cellsoncolytic vaccinia virusoncolytic virotherapyoncolytic virus

Authors and institutions

  • Department of Developmental Biology, School of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.
  • Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
  • Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Medical Genetics and Biotechnology Research Hub, Royan TuCAGene Ltd., Tehran, Iran.
  • Animal Core Facility, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Tehran, Iran.
  • Department of Biochemistry, School of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran.

ORCID profiles: Seyedeh Nasim Mirbahari, Davood Sanooghi, Marzieh Ebrahimi, Hamid Mahdizadeh, Ali Davari, Amir-Abbas Hedayati Asl, Sahel Ahmadpour Torkamani, Mahdi Hesaraki, Mehdi Totonchi

Funding

  • Royan Lotus Charity Foundation
  • Royan Institute
  • Royan TuCAGene Ltd
  • Kian Immune Cell Ltd
  • Iran National Science Foundation

Cite

APA

Mirbahari, S. N., Sanooghi, D., Ebrahimi, M., Mahdizadeh, H., Davari, A., Asl, A. H., Torkamani, S. A., Hesaraki, M., & Totonchi, M. (2026). Preliminary Insights Into the Combined Antitumor Efficacy of Onco‐VV‐TT and Natural Killer Cells in Glioblastoma. Cell Biology International, 50(6). https://doi.org/10.1002/cbin.70176

Vancouver

Mirbahari SN, Sanooghi D, Ebrahimi M, Mahdizadeh H, Davari A, Asl AH, et al. Preliminary Insights Into the Combined Antitumor Efficacy of Onco‐VV‐TT and Natural Killer Cells in Glioblastoma. Cell Biology International. 2026;50(6). doi:10.1002/cbin.70176

BibTeX
@article{Mirbahari2026,
  author = {Mirbahari, Seyedeh Nasim and Sanooghi, Davood and Ebrahimi, Marzieh and Mahdizadeh, Hamid and Davari, Ali and Asl, Amir-Abbas Hedayati and Torkamani, Sahel Ahmadpour and Hesaraki, Mahdi and Totonchi, Mehdi},
  title = {Preliminary Insights Into the Combined Antitumor Efficacy of Onco‐VV‐TT and Natural Killer Cells in Glioblastoma},
  journal = {Cell Biology International},
  year = {2026},
  volume = {50},
  number = {6},
  doi = {10.1002/cbin.70176}
}
Start for free →